A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are widely recommended for initial HIV-1 treatment. Bictegravir (BIC, B) is a novel, once-daily INSTI with potent antiviral activity being developed in coformulation with emtricitabine and tenofovir alafenamide (F/TAF). METHODS: In this Phase...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Sax, Paul E, Dejesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Wei, Lilian, White, Kirsten, Collins, Sean, Martin, Hal, Cheng, Andrew, Quirk, Erin
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630742/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1076
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires